Innovative research performed by Dr. Michael Rützler together with Søren Nielsen, MD, and Prof. Per Kjellbom from Lund University has led to the concept that aquaporin inhibitors can be developed into a therapy for the high blood glucose levels in diabetes patients.

 Based on this research, an initially performed drug discovery program resulted in potent and selective small molecule aquaporin inhibitors. Apoglyx will focus on the preclinical development and the commercialization of patented Aquaporin technology.